Application of marker based on TAZ level of single exosome transcription factor in serum in preparation of diagnosis for treating lung cancer

Abstract

The invention provides application of a marker based on the level of a single exosome transcription factor TAZ in serum in preparation of a lung cancer diagnosis, and finds that the level of the single exosome transcription factor TAZ is obviously reduced in the lung cancer serum for the first time, and the single exosome transcription factor TAZ can also be used as a negative marker for lung cancer diagnosis; the detection method comprises the following steps: ultracentrifuging serum to obtain exosomes, resuspending the exosomes by using a phosphate buffer salt solution, carrying out concentration detection, splitting the same amount of exosomes, detecting the content of TAZ in the same amount of exosomes, and dividing the obtained value by the amount of exosomes to obtain the protein level of TAZ in a single exosome. The exosome marker disclosed by the invention is based on the level of transcription factor TAZ protein in a single exosome, and the reliability of the marker can be improved based on analysis of equivalent exosomes; as a negative marker, the exosome TAZ protein level can be combined with other positive markers or negative markers in serum, so that the disease detection accuracy is improved.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to detecting the level of exosome protein from blood as a marker for lung cancer diagnosis, in particular to the content of transcription factor TAZ in a single exosome. Background technique [0002] Lung cancer is currently the malignant tumor with the highest morbidity and mortality in China and even in the world. Lung cancer is generally insidious at the time of onset, and the early symptoms are not obvious, so it is easily ignored by patients. The patient had already developed distant metastases at the time of presentation. Among patients with obvious symptoms, 75% have already developed metastases or are locally advanced, and 50-60% of patients develop distant metastases during treatment. In addition, the efficacy of lung cancer has not been significantly improved, and the five-year survival rate is only 18%. The root cause is the lack of early diagnosis. At present, there ...

AI Technical Summary

Problems solved by technology

At present, there is no report about exosomal TAZ protein in malignant tumors in the prior art and literature

Images